TY - CHAP M1 - Book, Section TI - Pancreatic Cancer A1 - Clark, Jeffrey W. A2 - Chabner, Bruce A. A2 - Longo, Dan L. Y1 - 2016 N1 - T2 - Harrison's Manual of Oncology, 2e AB - For most patients, pancreatic adenocarcinoma remains highly lethal and is the fourth leading cause of deaths from cancer in the USA. Less than 5% survive 5 years after diagnosis. Surgical resection is the only curative treatment. However, the cure rate with surgery is only 18%–25% and most patients are not surgical candidates. Patients with unresectable disease can have symptoms palliated by chemotherapy and/or radiation therapy. However, these have not significantly impacted 5-year survival. Improved understanding of pancreatic cancer biology continues to provide new therapeutic ideas. Trials are evaluating whether new approaches to earlier diagnosis or improvements in radiation therapy, chemotherapy (including targeted therapy), and/or immunotherapy (e.g., vaccines, therapy aimed at inhibiting negative immunoregulatory proteins) can impact survival. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/10/04 UR - hemonc.mhmedical.com/content.aspx?aid=1127648839 ER -